title: GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.
abstract: Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases, and its incidence has been increasing recently. In addition to hepatic complications, NAFLD is also recognized as an independent risk factor for cardiovascular disease. Unfortunately, the current therapies for NAFLD display variable efficacy; a novel and effective drug is urgently needed. Glucagon-like peptide-1 (GLP-1), a receptor agonist is a new drug approved for treating type 2 diabetes. Recently, these types of agents have shown a novel therapeutic effect on NAFLD. However, the mechanisms of GLP-1 receptor agonists on the treatment of NAFLD have not yet been explained precisely. Recent studies have demonstrated that GLP-1 reverses the progression of NAFLD not only indirectly through an incretin effect that improves key parameters involved in NAFLD, but also a direct effect on lipid metabolism of hepatocytes and inflammation in liver. In this review, we provided an overview of the role and mechanisms of GLP-1 in the therapy of NAFLD.
authors: Department of Endocrinology, Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, 100020, People's Republic of China.
authors: Jia
authors: J
authors: Liu
authors: Guang
authors: G
authors: Wang
authors: Yumei
authors: Y
authors: Jia
authors: Yuan
authors: Y
authors: Xu
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D018450:Disease Progression; D059865:Endoplasmic Reticulum Stress / Q000187:drug effects; D000067757:Glucagon-Like Peptide-1 Receptor / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008082:Lipotropic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D008099:Liver / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D008954:Models, Biological; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology; D018384:Oxidative Stress / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D008082:Lipotropic Agents; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
keywords: glucagon-like peptide-1; lipid metabolism; non-alcoholic fatty liver disease